A Proposed Roadmap for Parkinson’s Disease Proof of Concept Clinical Trials Investigating Compounds Targeting Alpha-Synuclein
暂无分享,去创建一个
J. Eberling | J. Cedarbaum | P. Brundin | A. Espay | W. Maetzler | K. Merchant | L. Menalled | K. Dave | A. Stoessl | J. Luthman | S. Hutten | Monica Javidnia | Alyssa Reimer | D. Weiner | Kalpana M. Merchant | David M. Weiner | M. Javidnia
[1] Donald A. Berry,et al. Design of a Bayesian adaptive phase 2 proof-of-concept trial for BAN2401, a putative disease-modifying monoclonal antibody for the treatment of Alzheimer's disease , 2016, Alzheimer's & dementia.
[2] Ji Hyun Ko,et al. Parkinson's disease cognitive network correlates with caudate dopamine , 2013, NeuroImage.
[3] Martijn L T M Müller,et al. Cholinergic Dysfunction in Parkinson’s Disease , 2013, Current Neurology and Neuroscience Reports.
[4] V. Sossi,et al. Effect of Dopamine Loss and the Metabolite 3-O-Methyl-[18F]Fluoro-dopa on the Relation between the 18F-Fluorodopa Tissue Input Uptake Rate Constant Kocc and the [18F]Fluorodopa Plasma Input Uptake Rate Constant Ki , 2003, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[5] V. Sossi,et al. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease , 2000, Annals of neurology.
[6] E. Yoshikawa,et al. Microglial activation and dopamine terminal loss in early Parkinson's disease , 2005, Annals of neurology.
[7] T. Dall,et al. The current and projected economic burden of Parkinson's disease in the United States , 2013, Movement disorders : official journal of the Movement Disorder Society.
[8] Michael J. Devine,et al. Parkinson's disease and α‐synuclein expression , 2011, Movement disorders : official journal of the Movement Disorder Society.
[9] W Fernandez,et al. Impaired activation of the supplementary motor area in Parkinson's disease is reversed when akinesia is treated with apomorphine , 1992, Annals of neurology.
[10] P. Mcgeer,et al. Reactive microglia are positive for HLA‐DR in the substantia nigra of Parkinson's and Alzheimer's disease brains , 1988, Neurology.
[11] K. Rhodes,et al. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease , 2016, Nature.
[12] H. Berendse,et al. Functional connectivity and cognitive decline over 3 years in Parkinson disease , 2014, Neurology.
[13] Daniela Berg,et al. Advances in markers of prodromal Parkinson disease , 2016, Nature Reviews Neurology.
[14] C. Adler,et al. The Search for a Peripheral Biopsy Indicator of &agr;-Synuclein Pathology for Parkinson Disease , 2017, Journal of neuropathology and experimental neurology.
[15] S. Friend,et al. The mPower study, Parkinson disease mobile data collected using ResearchKit , 2016, Scientific Data.
[16] J. Trojanowski,et al. Pathological α-Synuclein Transmission Initiates Parkinson-like Neurodegeneration in Nontransgenic Mice , 2012, Science.
[17] A. Björklund,et al. Impaired neurotransmission caused by overexpression of α-synuclein in nigral dopamine neurons , 2012, Proceedings of the National Academy of Sciences.
[18] R. Albin,et al. Olfactory dysfunction, central cholinergic integrity and cognitive impairment in Parkinson’s disease , 2010, Brain : a journal of neurology.
[19] R. Freeman,et al. Cutaneous Autonomic Pilomotor Testing to Unveil the Role of Neuropathy Progression in Early Parkinson’s Disease (CAPTURE PD): Protocol for a Multicenter Study , 2017, Front. Neurol..
[20] Karl Herrup,et al. The case for rejecting the amyloid cascade hypothesis , 2015, Nature Neuroscience.
[21] T. Hendler,et al. Cerebral pathological and compensatory mechanisms in the premotor phase of leucine-rich repeat kinase 2 parkinsonism. , 2012, Brain : a journal of neurology.
[22] M. Giugliano,et al. α-Synuclein strains cause distinct synucleinopathies after local and systemic administration , 2015, Nature.
[23] Martin Styner,et al. The pattern of gray matter atrophy in Parkinson’s disease differs in cortical and subcortical regions , 2015, Journal of Neurology.
[24] Michael W. Weiner,et al. Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014 , 2015, Alzheimer's & Dementia.
[25] E Ray Dorsey,et al. The Parkinson Pandemic-A Call to Action. , 2018, JAMA neurology.
[26] Chris C. Tang,et al. Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis , 2010, The Lancet Neurology.
[27] Lih-Fen Lue,et al. Amyloid Beta and Tau as Alzheimer’s Disease Blood Biomarkers: Promise From New Technologies , 2017, Neurology and Therapy.
[28] Carlo Alberto Artusi,et al. Integration of technology-based outcome measures in clinical trials of Parkinson and other neurodegenerative diseases. , 2018, Parkinsonism & related disorders.
[29] J. Trojanowski,et al. Initiation and Synergistic Fibrillization of Tau and Alpha-Synuclein , 2003, Science.
[30] John Q Trojanowski,et al. Widespread transneuronal propagation of α-synucleinopathy triggered in olfactory bulb mimics prodromal Parkinson’s disease , 2016, The Journal of experimental medicine.
[31] M. Andjelkovic,et al. A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease , 2017, Alzheimer's Research & Therapy.
[32] W. Pirker,et al. Correlation of striatal dopamine transporter imaging with post mortem substantia nigra cell counts , 2014, Movement disorders : official journal of the Movement Disorder Society.
[33] Jaap H. van Dieën,et al. Physical Performance and Physical Activity in Older Adults: Associated but Separate Domains of Physical Function in Old Age , 2015, PloS one.
[34] D J Brooks,et al. Delayed recovery of movement‐related cortical function in Parkinson's disease after striatal dopaminergic grafts , 2000, Annals of neurology.
[35] J. Kordower,et al. Therapeutic approaches to target alpha-synuclein pathology , 2017, Experimental Neurology.
[36] Jia-Yi Li,et al. Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in rats , 2014, Acta Neuropathologica.
[37] J Q Trojanowski,et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. , 2001, The New England journal of medicine.
[38] N. Bohnen,et al. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. , 2003, Archives of neurology.
[39] A. Schapira,et al. Molecular changes in the postmortem parkinsonian brain , 2016, Journal of neurochemistry.
[40] H. Shill,et al. Prevalence of Submandibular Gland Synucleinopathy in Parkinson's Disease, Dementia with Lewy Bodies and other Lewy Body Disorders. , 2016, Journal of Parkinson's disease.
[41] Alan A. Wilson,et al. Imaging Striatal Microglial Activation in Patients with Parkinson’s Disease , 2015, PloS one.
[42] T. Hendler,et al. Neural correlates of executive functions in healthy G2019S LRRK2 mutation carriers , 2013, Cortex.
[43] T. Videen,et al. Validation of nigrostriatal positron emission tomography measures: Critical limits , 2013, Annals of neurology.
[44] D. Berg,et al. Progression markers of motor deficits in Parkinson's disease: A biannual 4‐year prospective study , 2017, Movement disorders : official journal of the Movement Disorder Society.
[45] M. Hur,et al. Expression Patterns of α-Synuclein in Human Hematopoietic Cells and in Drosophila at Different Developmental Stages , 2000 .
[46] Elliott W. Dirr,et al. Intrastriatal injection of pre-formed mouse α-synuclein fibrils into rats triggers α-synuclein pathology and bilateral nigrostriatal degeneration , 2015, Neurobiology of Disease.
[47] Terina N. Martinez,et al. Best Practices for Generating and Using Alpha-Synuclein Pre-Formed Fibrils to Model Parkinson’s Disease in Rodents , 2018, Journal of Parkinson's disease.
[48] John L. Robinson,et al. Cellular Milieu Imparts Distinct Pathological α-Synuclein Strains in α-Synucleinopathies , 2018, Nature.
[49] Philippe Amouyel,et al. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. , 2004, Lancet.
[50] A. Björklund,et al. Modeling Parkinson’s disease pathology by combination of fibril seeds and α-synuclein overexpression in the rat brain , 2017, Proceedings of the National Academy of Sciences.
[51] Mark P. MacEachern,et al. Amyloid deposition in Parkinson's disease and cognitive impairment: A systematic review , 2015, Movement disorders : official journal of the Movement Disorder Society.
[52] Adnan Khan,et al. Corneal Confocal Microscopy: An Imaging Endpoint for Axonal Degeneration in Multiple Sclerosis. , 2017, Investigative ophthalmology & visual science.
[53] R. Bowtell,et al. Visualization of nigrosome 1 and its loss in PD , 2013, Neurology.
[54] Abid Oueslati. Implication of Alpha-Synuclein Phosphorylation at S129 in Synucleinopathies: What Have We Learned in the Last Decade? , 2016, Journal of Parkinson's disease.
[55] D. Brooks,et al. In-vivo staging of pathology in REM sleep behaviour disorder: a multimodality imaging case-control study , 2018, The Lancet Neurology.
[56] P. Kempster,et al. The Significance of α-Synuclein, Amyloid-β and Tau Pathologies in Parkinson's Disease Progression and Related Dementia , 2013, Neurodegenerative Diseases.
[57] Nick C Fox,et al. Cerebrospinal fluid in the differential diagnosis of Alzheimer’s disease: clinical utility of an extended panel of biomarkers in a specialist cognitive clinic , 2018, Alzheimer's Research & Therapy.
[58] I. Peñuelas,et al. The nigrostriatal system in the presymptomatic and symptomatic stages in the MPTP monkey model: A PET, histological and biochemical study , 2012, Neurobiology of Disease.
[59] Luca Mainardi,et al. Neuromelanin Imaging and Dopaminergic Loss in Parkinson's Disease , 2016, Front. Aging Neurosci..
[60] R. Albin,et al. In Vivo Imaging of Human Cholinergic Nerve Terminals with (–)-5-18F-Fluoroethoxybenzovesamicol: Biodistribution, Dosimetry, and Tracer Kinetic Analyses , 2014, The Journal of Nuclear Medicine.
[61] A. Björklund,et al. Parkinson-Like Neurodegeneration Induced by Targeted Overexpression of α-Synuclein in the Nigrostriatal System , 2002, The Journal of Neuroscience.
[62] J. Trojanowski,et al. Molecular and Biological Compatibility with Host Alpha-Synuclein Influences Fibril Pathogenicity. , 2016, Cell reports.
[63] R. D'Hooge,et al. rAAV2/7 vector-mediated overexpression of alpha-synuclein in mouse substantia nigra induces protein aggregation and progressive dose-dependent neurodegeneration , 2013, Molecular Neurodegeneration.
[64] Guy B. Williams,et al. Baseline and longitudinal grey matter changes in newly diagnosed Parkinson’s disease: ICICLE-PD study , 2015, Brain : a journal of neurology.
[65] Klaus Seppi,et al. Visualization of nigrosome 1 and its loss in PD: Pathoanatomical correlation and in vivo 7T MRI , 2014, Neurology.
[66] Claude Nahmias,et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL‐PET study , 2003, Annals of neurology.
[67] M. Chesselet,et al. Animal models of the non-motor features of Parkinson's disease , 2012, Neurobiology of Disease.
[68] L. Shaw,et al. Cerebrospinal fluid, plasma, and saliva in the BioFIND study: Relationships among biomarkers and Parkinson's disease Features , 2017, Movement disorders : official journal of the Movement Disorder Society.
[69] D. Hill,et al. Enrichment of clinical trials in MCI due to AD using markers of amyloid and neurodegeneration , 2016, Neurology.
[70] J. Sevigny,et al. Amyloid PET Screening for Enrichment of Early-Stage Alzheimer Disease Clinical Trials: Experience in a Phase 1b Clinical Trial , 2016, Alzheimer disease and associated disorders.
[71] Ian A. Watson,et al. Dopamine Transporter Neuroimaging as an Enrichment Biomarker in Early Parkinson's Disease Clinical Trials: A Disease Progression Modeling Analysis , 2017, Clinical and translational science.
[72] J. Jankovic,et al. Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti–&agr;-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical Trial , 2018, JAMA neurology.
[73] R. Chervin,et al. Symptoms of rapid eye movement sleep behavior disorder are associated with cholinergic denervation in Parkinson disease , 2012, Annals of neurology.
[74] B. Mollenhauer,et al. Validation of electrochemiluminescence assays for highly sensitive and reproducible quantification of α-synuclein in cerebrospinal fluid. , 2017, Bioanalysis.
[75] C. Tanner,et al. Biomarker‐driven phenotyping in Parkinson's disease: A translational missing link in disease‐modifying clinical trials , 2017, Movement disorders : official journal of the Movement Disorder Society.
[76] Xuemei Huang,et al. Quantitative susceptibility mapping of the midbrain in Parkinson's disease , 2016, Movement disorders : official journal of the Movement Disorder Society.
[77] R. Barbour,et al. Red Blood Cells Are the Major Source of Alpha-Synuclein in Blood , 2008, Neurodegenerative Diseases.
[78] Joseph R. Patterson,et al. Induction of alpha-synuclein pathology in the enteric nervous system of the rat and non-human primate results in gastrointestinal dysmotility and transient CNS pathology , 2018, Neurobiology of Disease.
[79] D. Brooks,et al. Imaging Parkinson’s disease below the neck , 2017, npj Parkinson's Disease.
[80] Marguerite Wieler,et al. Midbrain iron content in early Parkinson disease , 2008, Neurology.
[81] Aneeka M Hancock,et al. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. , 2010, Brain : a journal of neurology.
[82] V. Sossi,et al. PBB3 imaging in Parkinsonian disorders: Evidence for binding to tau and other proteins , 2017, Movement disorders : official journal of the Movement Disorder Society.
[83] R. Mach,et al. Binding of the Radioligand SIL23 to α-Synuclein Fibrils in Parkinson Disease Brain Tissue Establishes Feasibility and Screening Approaches for Developing a Parkinson Disease Imaging Agent , 2013, PloS one.
[84] Max A. Little,et al. Technology in Parkinson's disease: Challenges and opportunities , 2016, Movement disorders : official journal of the Movement Disorder Society.
[85] Norbert Schuff,et al. Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort , 2018, Movement disorders : official journal of the Movement Disorder Society.
[86] D. Eidelberg,et al. Metabolic networks for assessment of therapy and diagnosis in Parkinson's disease , 2009, Movement disorders : official journal of the Movement Disorder Society.
[87] D. Brooks,et al. Depressive symptoms in PD correlate with higher 5-HTT binding in raphe and limbic structures , 2010, Neurology.
[88] S. Studenski,et al. History of falls in Parkinson disease is associated with reduced cholinergic activity , 2009, Neurology.
[89] Norbert Schuff,et al. Diffusion tensor imaging of the nigrostriatal fibers in Parkinson's disease , 2015, Movement disorders : official journal of the Movement Disorder Society.
[90] Alberto J Espay,et al. Disease Modification in Parkinson's Disease: Current Approaches, Challenges, and Future Considerations , 2018, Movement disorders : official journal of the Movement Disorder Society.
[91] C. Mazzà,et al. Free‐living monitoring of Parkinson's disease: Lessons from the field , 2016, Movement disorders : official journal of the Movement Disorder Society.
[92] Roger N Gunn,et al. An 18-kDa Translocator Protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28 , 2011, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[93] J. Seibyl,et al. Molecular Imaging Insights into Neurodegeneration: Focus on α-Synuclein Radiotracers , 2014, The Journal of Nuclear Medicine.
[94] DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Parkinson Study Group. , 1989, Archives of neurology.
[95] M. Frasier,et al. α-synuclein imaging: a critical need for Parkinson's disease research. , 2013, Journal of Parkinson's disease.
[96] P. Tariot,et al. Randomized Trial of Verubecestat for Mild‐to‐Moderate Alzheimer's Disease , 2018, The New England journal of medicine.
[97] A. Snyder,et al. CSF proteins and resting-state functional connectivity in Parkinson disease , 2015, Neurology.
[98] M. Esiri,et al. Alpha‐synuclein RT‐QuIC in the CSF of patients with alpha‐synucleinopathies , 2016, Annals of clinical and translational neurology.
[99] Takahiko Tokuda,et al. Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson’s disease , 2016, Molecular Neurodegeneration.
[100] T. Ben-Hur,et al. Total and Proteinase K-Resistant α-Synuclein Levels in Erythrocytes, Determined by their Ability to Bind Phospholipids, Associate with Parkinson’s Disease , 2015, Scientific Reports.
[101] J. Trojanowski,et al. Spread of aggregates after olfactory bulb injection of α-synuclein fibrils is associated with early neuronal loss and is reduced long term , 2017, Acta Neuropathologica.
[102] M. Hur,et al. Expression patterns of alpha-synuclein in human hematopoietic cells and in Drosophila at different developmental stages. , 2000, Molecules and cells.
[103] Masayuki Satoh,et al. A longitudinal study of neuromelanin-sensitive magnetic resonance imaging in Parkinson’s disease , 2016, Neuroscience Letters.
[104] Chuong B. Do,et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson’s disease , 2014, Nature Genetics.
[105] P. Kahle. alpha-Synucleinopathy models and human neuropathology: similarities and differences. , 2008, Acta neuropathologica.
[106] V. Sossi,et al. Serotonin transporter binding and motor onset of Parkinson's disease in asymptomatic LRRK2 mutation carriers: a cross-sectional study , 2017, The Lancet Neurology.
[107] Jae Sung Lee,et al. Putaminal serotonergic innervation , 2015, Neurology.
[108] P. Kahle. α-Synucleinopathy models and human neuropathology: similarities and differences , 2007, Acta Neuropathologica.
[109] P. Brundin,et al. Review: Spreading the word: precise animal models and validated methods are vital when evaluating prion‐like behaviour of alpha‐synuclein , 2016, Neuropathology and applied neurobiology.
[110] M. Chesselet,et al. Transgenic rodent models to study alpha-synuclein pathogenesis, with a focus on cognitive deficits. , 2015, Current topics in behavioral neurosciences.
[111] Vesna Sossi,et al. A double‐blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease , 2003, Annals of neurology.
[112] Dorothee P Auer,et al. In Vivo Assessment of Brainstem Depigmentation in Parkinson Disease: Potential as a Severity Marker for Multicenter Studies. , 2017, Radiology.
[113] Janel O. Johnson,et al. α-Synuclein Locus Triplication Causes Parkinson's Disease , 2003, Science.
[114] D. Dickson,et al. Parkinson’s disease: experimental models and reality , 2017, Acta Neuropathologica.
[115] David M Holtzman,et al. Human amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo , 2006, Nature Medicine.
[116] Interpreting Alzheimer’s disease clinical trials in light of the effects on amyloid-β , 2014, Alzheimer's Research & Therapy.
[117] B. Vidakovic,et al. Breath Analysis by Mass Spectrometry: A New Tool for Breast Cancer Detection? , 2011, The American surgeon.
[118] V. Sossi,et al. Longitudinal evolution of compensatory changes in striatal dopamine processing in Parkinson's disease. , 2011, Brain : a journal of neurology.
[119] C. Rowe,et al. In vitro characterisation of BF227 binding to alpha-synuclein/Lewy bodies. , 2009, European journal of pharmacology.
[120] Philippe Amouyel,et al. α-synuclein locus duplication as a cause of familial Parkinson's disease , 2004, The Lancet.
[121] Yasuo Terayama,et al. Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson's disease , 2006, Neuroreport.
[122] V. Sossi,et al. Phosphorylated α-synuclein in Parkinson’s disease: correlation depends on disease severity , 2015, Acta Neuropathologica Communications.
[123] Jacob I. Ayers,et al. Intramuscular injection of α-synuclein induces CNS α-synuclein pathology and a rapid-onset motor phenotype in transgenic mice , 2014, Proceedings of the National Academy of Sciences.
[124] W. Poewe,et al. Meta‐analysis of dorsolateral nigral hyperintensity on magnetic resonance imaging as a marker for Parkinson's disease , 2017, Movement disorders : official journal of the Movement Disorder Society.
[125] A. Recasens,et al. In vivo models of alpha-synuclein transmission and propagation , 2018, Cell and Tissue Research.
[126] C. Adler,et al. The Systemic Synuclein Sampling Study: toward a biomarker for Parkinson's disease. , 2017, Biomarkers in medicine.
[127] Evžen Růžička,et al. Automated analysis of connected speech reveals early biomarkers of Parkinson’s disease in patients with rapid eye movement sleep behaviour disorder , 2017, Scientific Reports.
[128] R. Melki. Role of Different Alpha-Synuclein Strains in Synucleinopathies, Similarities with other Neurodegenerative Diseases , 2015, Journal of Parkinson's disease.
[129] D. Standaert,et al. How can rAAV‐α‐synuclein and the fibril α‐synuclein models advance our understanding of Parkinson's disease? , 2016, Journal of neurochemistry.
[130] D. Standaert,et al. Targeted Overexpression of Human &agr;-Synuclein Triggers Microglial Activation and an Adaptive Immune Response in a Mouse Model of Parkinson Disease , 2008, Journal of neuropathology and experimental neurology.
[131] V. Dhawan,et al. Changes in network activity with the progression of Parkinson's disease. , 2007, Brain : a journal of neurology.
[132] E. Bézard,et al. Alpha‐synuclein propagation: New insights from animal models , 2016, Movement disorders : official journal of the Movement Disorder Society.
[133] J. Brotchie,et al. Animal models of α-synucleinopathy for Parkinson disease drug development , 2017, Nature Reviews Neuroscience.
[134] P. Brundin,et al. Transfer of human α-synuclein from the olfactory bulb to interconnected brain regions in mice , 2013, Acta Neuropathologica.
[135] Fumitoshi Kodaka,et al. Principal Component Analysis of Multimodal Neuromelanin MRI and Dopamine Transporter PET Data Provides a Specific Metric for the Nigral Dopaminergic Neuronal Density , 2016, PloS one.
[136] J. Kordower,et al. Novel oligodendroglial alpha synuclein viral vector models of multiple system atrophy: studies in rodents and nonhuman primates , 2017, Acta Neuropathologica Communications.
[137] M. Chesselet,et al. Alpha-synuclein and transgenic mouse models , 2004, Neurobiology of Disease.
[138] M. Cookson,et al. Genetic neuropathology of Parkinson's disease. , 2008, International journal of clinical and experimental pathology.
[139] M. Hasegawa,et al. Propagation of pathological α-synuclein in marmoset brain , 2017, Acta Neuropathologica Communications.
[140] P. Mcgeer,et al. Inflammation and neurodegeneration in Parkinson's disease. , 2004, Parkinsonism & related disorders.
[141] B. Mollenhauer,et al. Development of a Biochemical Diagnosis of Parkinson Disease by Detection of &agr;-Synuclein Misfolded Aggregates in Cerebrospinal Fluid , 2017, JAMA neurology.
[142] C. Adler,et al. Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. , 2013, Brain : a journal of neurology.
[143] Arthur W. Toga,et al. CSF biomarkers associated with disease heterogeneity in early Parkinson’s disease: the Parkinson’s Progression Markers Initiative study , 2016, Acta Neuropathologica.
[144] R. Takahashi,et al. Inoculation of α-synuclein preformed fibrils into the mouse gastrointestinal tract induces Lewy body-like aggregates in the brainstem via the vagus nerve , 2018, Molecular Neurodegeneration.
[145] A. Singleton,et al. The Parkinson Progression Marker Initiative (PPMI) , 2011, Progress in Neurobiology.
[146] Walter Maetzler,et al. Twelve‐week sensor assessment in Parkinson's disease: Impact on quality of life , 2016, Movement disorders : official journal of the Movement Disorder Society.
[147] H. Braak,et al. Staging of brain pathology related to sporadic Parkinson’s disease , 2003, Neurobiology of Aging.
[148] M. Chesselet,et al. In vivo alpha-synuclein overexpression in rodents: A useful model of Parkinson's disease? , 2008, Experimental Neurology.
[149] D. Selkoe,et al. A user's guide for α‐synuclein biomarker studies in biological fluids: Perianalytical considerations , 2017, Movement disorders : official journal of the Movement Disorder Society.
[150] Arthur W. Toga,et al. Precompetitive Data Sharing as a Catalyst to Address Unmet Needs in Parkinson’s Disease , 2015, Journal of Parkinson's disease.
[151] Paul A Wetzel,et al. Pervasive ocular tremor in patients with Parkinson disease. , 2012, Archives of neurology.
[152] V. Lee,et al. Distinct α-Synuclein strains and implications for heterogeneity among α-Synucleinopathies , 2018, Neurobiology of Disease.
[153] Bastiaan R Bloem,et al. Comparison of a timed motor test battery to the Unified Parkinson's Disease Rating Scale‐III in Parkinson's disease , 2008, Movement disorders : official journal of the Movement Disorder Society.
[154] Ole Isacson,et al. Dynamic Changes in Presynaptic and Axonal Transport Proteins Combined with Striatal Neuroinflammation Precede Dopaminergic Neuronal Loss in a Rat Model of AAV α-Synucleinopathy , 2009, The Journal of Neuroscience.
[155] Alexander Hammers,et al. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease , 2006, Neurobiology of Disease.
[156] J. Rowe,et al. Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be? , 2017, Movement disorders : official journal of the Movement Disorder Society.
[157] Keith A. Johnson,et al. Tau Positron Emission Tomographic Imaging in the Lewy Body Diseases. , 2016, JAMA neurology.
[158] Walter Maetzler,et al. New methods for the assessment of Parkinson's disease (2005 to 2015): A systematic review , 2016, Movement disorders : official journal of the Movement Disorder Society.
[159] D. Galasko,et al. Autophagy inhibition promotes SNCA/alpha-synuclein release and transfer via extracellular vesicles with a hybrid autophagosome-exosome-like phenotype , 2018, Autophagy.
[160] R. Crowther,et al. α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies , 1998 .
[161] C. Tanner,et al. A longitudinal program for biomarker development in Parkinson's disease: A feasibility study , 2009, Movement disorders : official journal of the Movement Disorder Society.
[162] Keith A. Johnson,et al. The Evolution of Preclinical Alzheimer’s Disease: Implications for Prevention Trials , 2014, Neuron.
[163] Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. , 2002, JAMA.
[164] G. Grossberg,et al. Analysis of recent failures of disease modifying therapies in Alzheimer’s disease suggesting a new methodology for future studies , 2017, Expert review of neurotherapeutics.
[165] J. Schott,et al. Blood Biomarkers for Alzheimer’s Disease: Much Promise, Cautious Progress , 2017, Molecular Diagnosis & Therapy.
[166] V. Sossi,et al. Longitudinal progression of sporadic Parkinson's disease: a multi-tracer positron emission tomography study. , 2009, Brain : a journal of neurology.
[167] A. Björklund,et al. Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of α-synuclein in midbrain dopamine neurons , 2012, Neurobiology of Disease.
[168] Khaled Bouri,et al. Scientific and regulatory reasons for delay and denial of FDA approval of initial applications for new drugs, 2000-2012. , 2014, JAMA.
[169] B. Mollenhauer,et al. The utility of α-synuclein as biofluid marker in neurodegenerative diseases: a systematic review of the literature. , 2016, Biomarkers in medicine.
[170] F. Turkheimer,et al. Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients. , 2014, The Journal of clinical investigation.
[171] D. Vaillancourt,et al. Longitudinal changes in free-water within the substantia nigra of Parkinson's disease. , 2015, Brain : a journal of neurology.
[172] D B Calne,et al. Correlation of striatal fluorodopa uptake in the MPTP Monkey with dopaminergic indices , 1993, Annals of neurology.
[173] M. Higuchi,et al. Fluorescence and autoradiographic evaluation of tau PET ligand PBB3 to α‐synuclein pathology , 2017, Movement disorders : official journal of the Movement Disorder Society.
[174] J. Trojanowski,et al. Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice , 2012, The Journal of experimental medicine.
[175] E. Tolosa,et al. Loss of dorsolateral nigral hyperintensity on 3.0 tesla susceptibility‐weighted imaging in idiopathic rapid eye movement sleep behavior disorder , 2016, Annals of neurology.
[176] J. Hardy,et al. A Critique of the Drug Discovery and Phase 3 Clinical Programs Targeting the Amyloid Hypothesis for Alzheimer Disease , 2014, Annals of neurology.
[177] H. Kimura,et al. Human positron emission tomographic [18F]Fluorodopa studies correlate with dopamine cell counts and levels , 1993, Annals of neurology.
[178] Alan C. Evans,et al. Network structure of brain atrophy in de novo Parkinson's disease , 2015, eLife.
[179] Qin Li,et al. Viral‐mediated oligodendroglial alpha‐synuclein expression models multiple system atrophy , 2017, Movement disorders : official journal of the Movement Disorder Society.
[180] Michael Tanen,et al. The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer’s disease patients , 2016, Science Translational Medicine.
[181] Jochen Klucken,et al. Dopaminergic neuron loss and up‐regulation of chaperone protein mRNA induced by targeted over‐expression of alpha‐synuclein in mouse substantia nigra , 2007, Journal of neurochemistry.
[182] Yonatan Stelzer,et al. Parkinson-associated risk variant in enhancer element produces subtle effect on target gene expression , 2016, Nature.
[183] Alan A. Wilson,et al. Elevated serotonin transporter binding in depressed patients with Parkinson's disease: A preliminary PET study with [11C]DASB , 2008, Movement disorders : official journal of the Movement Disorder Society.
[184] A. Björklund,et al. Nigrostriatal α-synucleinopathy induced by viral vector-mediated overexpression of human α-synuclein: A new primate model of Parkinson's disease , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[185] M. B. Spraker,et al. High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease , 2009, Neurology.
[186] B. Dehay,et al. Alpha-synuclein-based models of Parkinson's disease. , 2016, Revue neurologique.
[187] R. Mach,et al. Radiosynthesis and in Vivo Evaluation of Two PET Radioligands for Imaging α-Synuclein , 2014, Applied sciences.
[188] Claudia Manfredi,et al. Analysis of facial expressions in parkinson's disease through video-based automatic methods , 2017, Journal of Neuroscience Methods.
[189] R. Ridley,et al. Long-term consequences of human alpha-synuclein overexpression in the primate ventral midbrain. , 2007, Brain : a journal of neurology.
[190] A. Lang,et al. How does parkinsonism start? Prodromal parkinsonism motor changes in idiopathic REM sleep behaviour disorder. , 2012, Brain : a journal of neurology.
[191] Oury Monchi,et al. Dysfunction of the default mode network in Parkinson disease: a functional magnetic resonance imaging study. , 2009, Archives of neurology.
[192] J. Langston,et al. Elevated Alpha-Synuclein Impairs Innate Immune Cell Function and Provides a Potential Peripheral Biomarker for Parkinson's Disease , 2013, PloS one.